198 related articles for article (PubMed ID: 9182213)
1. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
2. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
3. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
[TBL] [Abstract][Full Text] [Related]
4. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
[TBL] [Abstract][Full Text] [Related]
7. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS; Schechter MT; Rachlis A; Gill J; Beaulieu R; Tsoukas C; Raboud J; Cameron B; Salomon H; Dunkle L; Smaldone L; Wainberg MA
Ann Intern Med; 1995 Oct; 123(8):561-71. PubMed ID: 7677296
[TBL] [Abstract][Full Text] [Related]
8. The effects on survival of early treatment of human immunodeficiency virus infection.
Graham NM; Zeger SL; Park LP; Vermund SH; Detels R; Rinaldo CR; Phair JP
N Engl J Med; 1992 Apr; 326(16):1037-42. PubMed ID: 1347907
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Fischl MA; Parker CB; Pettinelli C; Wulfsohn M; Hirsch MS; Collier AC; Antoniskis D; Ho M; Richman DD; Fuchs E
N Engl J Med; 1990 Oct; 323(15):1009-14. PubMed ID: 1977079
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus infection in children.
Hoernle EH; Reid TE
Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
[TBL] [Abstract][Full Text] [Related]
14. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine.
Lipshultz SE; Orav EJ; Sanders SP; Hale AR; McIntosh K; Colan SD
N Engl J Med; 1992 Oct; 327(18):1260-5. PubMed ID: 1406818
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
[TBL] [Abstract][Full Text] [Related]
16. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
Domanski MJ; Sloas MM; Follmann DA; Scalise PP; Tucker EE; Egan D; Pizzo PA
J Pediatr; 1995 Jul; 127(1):137-46. PubMed ID: 7608800
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
18. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
19. Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
Nguyen BY; Yarchoan R; Wyvill KM; Venzon DJ; Pluda JM; Mitsuya H; Broder S
J Infect Dis; 1995 May; 171(5):1180-9. PubMed ID: 7751692
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
